

Formulation and development of polyherbal emulgel containing tridax procumbens l. & vranashodhak oil for wound healing activity.

¹Karale Ashwini R, ²Dr. Hingane Lahu D

²HOD

Department of Pharmacology
Aditya Pharmacy College, Beed
Maharashtra. 431122.

Abstract: The goal of this study is to produce a polyherbal wound healing product. Tridax procumbens L. Piperine & Vranashodhak oil were chosen for the current study based on these plants and herbal oil. As a result, these plants and herbal oil were chosen for the research. Piperine was reported as a bioenhancer for the Emulgel formulation, and the leaves of Tridax Procumbens L. and Vranashodhak oil were reported for rapid wound healing activities. The present study was conducted to formulate herbal Emulgel of Tridax procumbens L. Piperine & Vranashodhak oil using gelling agents like Carbopol 934. The prepared Emulgels were evaluated for physicochemical properties and for their pharmacological activity. The formulation has optimum gel consistency, viscosity, Spreadability. Emulgel has also shown reasonable stability in terms of drug content analysis and physicochemical characteristics. The wound healing activity of polyherbal Emulgel formulation was investigated by utilizing excision wound model. Safety evaluations of the Emulgels were proved to be free from skin irritation, the desirability of a topical product. Excision Wound healing studies of the Emulgel formulation revealed that Emulgel of Tridax procumbens L., Piperine, and Vranashodhak oil comparatively greater wound regeneration activity in comparison with Standard (Povidone iodine ointment USP1%), Placebo and untreated control groups. The polyherbal Emulgels, with Tridax procumbens L. leaf extract was successfully prepared and evaluated for assessing their safety, excision wound healing efficacy and pharmaceutical quality.

Keywords: Tridax procumbens L., Piperine, Vranashodhak oil, Emulgel, Wound Healing, Excision Wound Model.

I. INTRODUCTION

In traditional treatments like Ayurveda, Unani, and Siddha, herbal remedies serve as the foundation for the treatment and prevention of a variety of illnesses and disorders. Traditional and Western medicine both heavily rely on plant extracts. (5) Tridax procumbens L. is a member of the Asteraceae family and is known in Marathi as 'Dagdi Pala, kambarmodi' in Ayurvedic as Jayanthi and in English as Coat buttons/Mexican Daisy due to the appearance of its flowers. It is an ethnobotanically important. The plant has been described as a gregarious weed that can be found all across the tropics and subtropics. Tridax procumbens has a long history of use as a medication in Ayurvedic medicine for a number of ailments. Anti-diabetic, anti-inflammatory, anti-cancer, hepatoprotective, blood coagulation, and other pharmacological actions are linked to it. Tridax procumbens leaves have been used as a common cure for cutaneous wounds in India for centuries. Earlier workers have reported that it possesses antidiabetic(6), anti-bacterial, antiplasmodial(7), antihepatotoxic, anti-oxidant(8), antimicrobial(8), immunomodulatory(9), wound healing and anti-cancerous properties (10)

The Vranashodhak oil is folklore ayurvedic formulation that can be made from combination of many herbal swaras. This oil is useful in healing the wound quickly. It cleans the wound and prevent infection and pus formation. Each 10 ml of siddha taila is prepared by using aqueous extract of Nirgundi swaras (Vitex negundo)lf., Haritaki kwath (Terminalia chebula) frt. 0.1ml., Kanher swaras (Nerium indicum) lf., Kadulimb pala swasar (Azadirachta indica) lf., Dhotra (Datura metel) lf., 0.1ml each., Base Karanj tail (Pongamia pinnata)ol.10ml ref. Bhavaprakash.

Black pepper contains the presence of an alkaloid known as Piperine. Piperine can be found in the Piperaceae family's black, white, and long peppers. Piperine represents diverse biological activities, such as anti-inflammatory, anticancer, antiviral, anti-larvicidal, pesticide, anti-Alzheimer's, antidepressant and most importantly Piperine is known as the bioavailability enhancer.(11)

There are cream, ointment, and gel formulation was present in market for the Tridax procumbens L. but there is no combination of tridax procumbens L. and Vranashodhak Oil is not available in market so need to formulate this combination using Emulgel Formulation. Wound is defined as loss or breaking of cellular and anatomic or functional continuity of living tissue due to physical, chemical, thermal, microbial, or immunological exploitation of the tissues. Wound healing disorders present a serious clinical problem and are likely to increase when they are associated with diseases such as diabetes, hypertension, and obesity, etc.

Emulgel, a biphasic semi-solid formulation comprise of aqueous and non-aqueous phases, delivering both hydrophilic and lipophilic agents(2). Emulgel, are emulsions prepared by mixing with gums.(3) They're also quite good at penetrating the skin, Thixotropic, greaseless, easily spreadable, readily removable, emollient, non-staining, water-soluble, longer shelf life, bio friendly, translucent & appealing look are only a few of the benefits of Emulgels for dermatological treatment. Topical drug use necessitates an understanding of the factors that influenced percutaneous absorption.(4)

There are basically four stages of wound healing they are Hemostasis, Inflammations, Proliferation and Remouldings.

Plant review:**Table 1.2 Taxonomical Classification of *Tridax Procumbens* L.**

| <i>Tridax Procumbens</i> L. | |
|------------------------------------|---|
| Kingdom | : Plantae-plants |
| Sub-kingdom | : Tracheobionta- Vascular plants |
| Division | : Spermatophyta |
| Subdivision | : Magnoliophyta- flowering plants |
| Class | : Magnoliopsida- Dicotyledons |
| Subclass | : Asteridae |
| Order | : Asterales |
| Family | : Asteraceae- Aster Family |
| Genus | : <i>Tridax</i> L. -tridax |
| Species | : <i>Tridax procumbens</i> L. -coat buttons |

**Fig.1.1 *Tridax Procumbens* L.****Phytochemical review:**

Flavonoids, alkaloids, carotenoids, hydroxycinnamates, lignans, benzoic acid derivatives, phytosterols, tannins, raw proteins, soluble carbohydrates, and calcium oxide are said to be present in the leaf and other portions of *T. procumbens*. (12) Crude proteins make up 26% of the leaf of *Tridax*, along with crude fibre (17%), soluble carbohydrates (39%), calcium oxide (5%), and luteolin, glucoluteolin, quercetin, and isoquercetin, which have all been found in the plant's blossoms. While the plant has also been linked to fumaric acid, fl-sitosterol, and tannin.

2. MATERIAL AND METHODS**2.1. Materials:****Collection of Plant Samples and other excipients**

Leaves of *Tridax procumbens* L. were collected from different localities of Buldana. and its nearby areas and washed thoroughly with distilled water. The cleaned plant parts are then allowed for the complete shade drying and then made to fine powder with a mechanical grinder and stored in an airtight container.(10)

The plant *Tridax procumbens* L. were identified by D.L. SHIRODKAR BOTANIST Botanical Survey of India Western Regional Centre 7, Koregaon Park, Pune-411001. The Piperine obtained as a gift sample from Amsar pvt. Ltd. Indore., and Vranashodhak oil is a marketed formulation and is collected from Manikarnika Ayurvedalay Pune.

2.2. Preparation of Extract

Add 100 gm of finely divided powdered crude *Tridax Procumbens* L. in 500 ml of hydroalcoholic mixture (60:40) Keep it in a closed container for 72 hours with stirred time to time and filter it Allow to evaporate filtrate at 60-70°C & Collect the Semisolid extract.(10) The organoleptic/physical properties of Extract and oil was reported.

2.3. Preparation of *Tridax procumbens* L. & Vranashodhak oil Emulgel :

Gel Phase : Dissolve Carbopol 934 in purified water with Const. stirring at moderate speed using mechanical stirrer and adjust the pH [6-6.5] using triethanol amine.

Oil Phase : Dissolve span 20 (1.5ml) in sufficient quantity of Vranashodhak oil.

Aqueous Phase : a.) Dissolve tween 20 (1ml) in purified water to make Aq. Phase.

b.) Methyl paraben and propyl paraben was dissolved in propylene glycol

c.) Extract (*Tridax procumbens* L. + Piperine) dissolved in water

Then both b & c were mixed in Aqueous phase (a) Both Aqueous Phase & Oil Phase heated separately up to 70-80°C. Then Oil phase is added in Aqueous Phase with continuous stirring until it get cooled at room temperature Then the obtained Emulsion was mixed with gel in the 1:1 ratio.

2.4. Experimental Design

A central composite design was used to create and optimise the formulations. Nine confirmatory runs were created and their parameters assessed.

The formulation was optimized using a central composite design with two independent variables to estimate various parameters, interaction and also to evaluate the quadratic effects of ingredients on Tridax procumbens L. & Vranashodhak oil emulgel by constructing model using Design Expert (version 8.0.0, Stat-Ease Inc., Minneapolis, Minneta)

9 runs were generated for the responses alphabetically labelled as F1 to F9 having a concentration of the factors ranging from minimum to maximum as given in Table 1.

Table no. 2.1 Full Factorial Design layout

| Factor | Name | Unit | Type | Sub Type | Minimum | Maximum | Coded Low | Coded high | Mean | Std. Dev. |
|--------|------------------|------|---------|------------|------------|---------|-----------|------------|------|-----------|
| A | Carbopol 934 | gm | Numeric | Continuous | 0.585 8 | 3.41 | -1 ↔ 1.00 | +1 ↔ 3.00 | 2.00 | 1.0000 |
| B | Vranashodhak oil | mL | Numeric | Continuous | 1.48 | 5.02 | -1 ↔ 2.00 | +1 ↔ 4.50 | 3.25 | 1.25 |

2.5. Evaluation of Emulgel:

2.5.1. Organoleptic Properties:

The prepared extract and marketed oil and all the formulated Emulgels were visually inspected for colour, homogeneity, and phase separation after they have been settled in the container immediately as well as regularly for an interval of 15 days.(13)

2.5.2. Phytochemical Content of the Leaves Assessment :

Preliminary phytochemical screening of the Hydro-Ethanollic extract of Tridax procumbens L. was carried out by established methods.

2.5.3. HPTLC :

Table 2.2 Optimized HPTLC condition

| | |
|-------------------------------|---|
| Stationary Phase | Merck, TLC AI plate silica gel 60 F 254 |
| Plate format | 100 x 100 mm |
| Application type | Band |
| Application | Position Y: 8.0 mm, length: 8.0 mm, width: 0.0 mm |
| Track | First position X: 21.5 mm, distance: 11.4 mm |
| Solvent front position | 70 mm |
| Software | Sever LABSERVER, version 3.1.21109.3 |
| ATS 4 | S/N:250243 (NEW ATS4) |
| Mobile Phase | Toluene : Ethyl acetate (8:2 V/V) |
| Saturation time | 20 min |
| Mode of Separation | Normal Phase |
| Sample applicator | Camag Linomat V |
| Sample Solvent Type | Methanol |

2.5.4. Measurement of pH :

The prepared Emulgels were evaluated for pH in triplicate by taking 1 g of each emulgel in 10 mL beaker and measured the digital pH meter at room temperature

2.5.5. Particle size of emulsion and Emulgel:

Characterization of Optimized Formulations: Globule size and its distribution in Emulgels: This study was performed for the optimized batches each from Carbopol 934 based gels. Malvern zetasizer was used to determine globule size and dispersion. A 1.0 gm sample was dissolved in purified water and agitated to get homogeneous dispersion. Sample was injected to photocell of zetasizer. Mean globule diameter and distribution was obtained.

Photomicrography : Morphology of emulsion was studied under light microscope. The form of the Emulgel's optimised batches was examined under a light microscope. The emulgel was appropriately diluted, put on a glass slide, and studied under a 40 X light microscope.

2.5.6. Determination of Spreadability:

On the wooden block covered with an excess of the emulgel being studied, a ground glass slide was fixed. This slide is sandwiched with another second slide. The second slide is attached to a hook of the balance. In order to expel the air, a weight of 250 - 500 mg was placed on the top of the two slides for 5 min. The required quantity of weight was placed in the other pan which is attached to the pulley through a hook. It was noted how long it took the top slide to travel 5 cm. A shorter interval indicates a better spreading coefficient.(14)

2.5.7. Viscosity :

The viscosity of the formulated preparations was determined using brook field viscometer with spindle no. 64 (Brookfield Engineering Laboratories). The formulation whose viscosity was to be determined was added to a beaker covered with a thermostatic jacket. Spindle was allowed to pass into the emulgel, and the reading was noted at 30 rpm, the apparatus being maintained at 25 °C.(15)

2.5.8. Drug Content:

1g of prepared emulgel was mixed with methanol and was kept for shaking for 30 min. The solution was filtered and was diluted suitably using a phosphate buffer of 6.8 pH, and the absorbance was measured at 267 nm. From the absorbance reading percentage, drug content was calculated

2.5.9. In-vitro Release Studies :

The in vitro drug release from emulgel was carried out using Franz diffusion cell at 50 RPM and $37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$. Phosphate buffer was used as the dissolution medium. 1 ml of dissolution medium was withdrawn at predetermined time intervals and fresh dissolution medium was replaced. The sample were withdrawn at regular interval and analyzed by UV spectrophotometer at 267 nm for the presence of the drug.

2.5.10. Stability studies :

The prepared Emulgels were packed in aluminium collapsible tubes (5 g) and subjected to stability studies at 5°C , $25^{\circ}\text{C}/60\% \text{RH}$, $30^{\circ}\text{C}/65\% \text{RH}$, and $40^{\circ}\text{C}/75\% \text{RH}$ for a period of 3 months. Samples were withdrawn at 15-day time intervals and evaluated for physical appearance, pH, rheological properties and drug content (16)

2.5.11. Antimicrobial study:

We undertake a batch optimization observational study. First, the extract's MIC (minimum inhibitory concentration) was determined using the serial dilution method against Escherichia coli and Candida albicans. Using an agar disc- diffusion experiment, the Polyherbal Emulgel was tested against an E. Coli bacterial strain and Candida Albicans. The inhibitory zone was measured. The antibacterial activity of the polyherbal Emulgel was compared to a standard. A nutritional agar medium solution of 20 mL was made and placed in Petri plates. Allow some time for the media to be established. After that, we drilled 8 mm holes in Petri plates for our formulation, extract, and standard medicine to be poured into. All of the items that we will be using should be sterilized. After that, we performed bacterial inoculation. For bacteria and fungus, we need to incubate for 24 hours, and for their growth in Petri plates, we need to incubate for 48 hours. After that, a set incubation time zone was calculated

2.6. In vivo study for wound healing :

2.6.1. Experimental Design :

The rat were divided into four Group each consist of 6 rats

I.Group I (Normal control) : No topical treatment was given and its % Wound Contraction was calculated.

II.Group II (Placebo control): The rat was treated with Placebo Emulgel and its % wound contraction was calculated.

III.Group III (Standard control): The rat was treated with Povidone iodine Ointment 5% and its % wound contraction was calculated.

IV.Group IV (Optimized Formulation): The rat was treated with Tridax Emulgel Formulation and its % wound contraction was calculated.

2.6.2. Wound Healing model in rats:

Rats: Wister albino rats of either sex (body weight between 150-250 g) were used for wound healing activity. They were housed in standard environmental conditions, fed with standard pallet diet and water ad libitum.

Excision Wound Model :

In this model, a typical wound is created by cutting a circle skin in the dorsal region of the experimental animals under light ether anesthesia. A wound of 500 mm² is usually formed by marking a margin on a pre-shaved region using indelible ink and sealing it with a rubber closure. Morton and Malone used planimetric measures to assess the vulnerary activity of an open wound in rats. This model can also be used to investigate the wound healing phase. This is accomplished by photographing the wound at various time intervals during the healing process.(17)The percentage of the original wound that closes after a predetermined lap of time (in days) is used as a criterion. Separate cages are used to keep the animals. The time has come. The period of epithelization, that is, day of fall of eschar and the scar area, was also noted down.(18) (19)

$$\% \text{ Wound Contraction} = \left[\frac{\text{Initial Day Wound Size} - \text{Specific Day Wound size}}{\text{Initial Day Wound Size}} \right] \times 100$$

2.6.3. Determination of period of epithelization:

The dropping of the scab from the wound is considered as the wound healed, or as the end point of complete epithelization. The number of days required for these, are known as epithelization period.(20)

2.6.4. Histopathological study :

The healing tissues obtained on the 15th day from all four groups of animals of the incision wound model were processed for histopathological study (**PRADO, Preclinical Research and Development Organization, Pvt. Ltd. Pune**). The amount of collagen was quantified using Vangeison stain

3. RESULT AND DISCUSSION

3.1. Evaluation Parameters:

3.1.1 Organoleptic Properties:

the prepared extract and marketed oil were checked visually for physical appearance, texture, odor, nature are as given in following table no.

Table 3.1 Organoleptic Properties of Drugs

| Physical properties | Tridax procumbens L. | | Vranashodhak oil | |
|---------------------|----------------------|----------|------------------|--------------|
| | Observed | Reported | Observed | Reported |
| Appearance | Dark greenish | Green | Yellow | Yellow |
| Texture | smooth | Smooth | Less viscous | Less viscous |

| | | | | |
|---------------|-----------------|-----------------|-----------------|-----------------|
| Odor | Characteristics | Characteristics | Characteristics | Characteristics |
| Nature | Semi-solid | Powder | Liquid | Liquid |

Various formulations of the emulgel were checked visually for their homogeneity, color, phase separation and consistency, and it was observed that all the formulation F1 to F9 appeared homogenous, pale yellow having a smooth consistency without having any phase separation.

Table 3.2 Organoleptic properties of Emulgel Formulation.

| Formulation | Color | Homogeneity | Consistency |
|-------------|-----------------|-------------|-------------|
| F1 | Greenish yellow | + | Uniform |
| F2 | Greenish yellow | + | Uniform |
| F3 | Light yellow | + | Uniform |
| F4 | Yellow | + | Uniform |
| F5 | Light yellow | + | Uniform |
| F6 | Light yellow | + | Uniform |
| F7 | Light yellow | + | Uniform |
| F8 | Yellow | + | Uniform |
| F9 | Yellow | + | Uniform |

1.1. Phytochemical Study of Tridax procumbens L. Hydro-Ethanolic Leaf Extract

The phytochemical screening of Tridax procumbens Hydro-Ethanolic extract showed the presence of Alkaloids, Carotenoids, Flavonoids, Saponins, Tannins, were presented (Table). The phytochemical constituents indicate.

Table. 3.3 Qualitative profile of phytochemicals founds in Tridax Procumbens Leaves.

| Sr. no. | Phytochemicals | Status |
|---------|----------------|--------|
| 1. | Alkaloid | + |
| 2. | Carotenoids | ++ |
| 3. | Flavonoids | + |
| 4. | Saponins | + |
| 5. | Tannins | ++ |

1.2. HPTLC :




Fig. 3.1 Photo-documentation of Tridax procumbens L.

Description: Tridax procumbens L. 200mg/10ml in water : Ethanol 60:40 v/v

Volume: 15.0 µl




Fig.3.2 HPTLC Profile of Hydro-Ethanollic Extract of Whole Plant of *Tridax procumbens* Linn

Table. 3.4 Track 6. Data of *Tridax procumbens* L.

| Peak # | Start | | Max | | | End | | Area | | Manual peak | Substance Name |
|--------|----------------|--------|----------------|--------|-------|----------------|--------|---------|-------|-------------|----------------|
| | R _F | H | R _F | H | % | R _F | H | A | % | | |
| 1 | 0.065 | 0.0000 | 0.094 | 0.0797 | 21.42 | 0.102 | 0.0663 | 0.00160 | 12.16 | No | |
| 2 | 0.103 | 0.0657 | 0.118 | 0.1029 | 27.66 | 0.142 | 0.0000 | 0.00242 | 18.35 | No | |
| 3 | 0.250 | 0.0000 | 0.302 | 0.1155 | 31.05 | 0.340 | 0.0000 | 0.00412 | 31.33 | No | |
| 4 | 0.453 | 0.0028 | 0.505 | 0.0385 | 10.36 | 0.550 | 0.0183 | 0.00214 | 16.25 | No | |
| 5 | 0.795 | 0.0090 | 0.866 | 0.0353 | 9.50 | 0.960 | 0.0000 | 0.00288 | 21.90 | No | |

1.3. Measurement of pH: The pH readings were taken as an average of three sample readings. The values exhibited by the Emulgels are found to be in the range of 5.85 to 6.87. Hence all the formulations were in the normal pH range of the skin

1.4. Particle size of Emulsion and Emulgel:

Globule size and its distribution in emulgel Mean globule size in formulation was found to be 386.6 nm and zeta potential was -19.6 mv.

Photomicrography The suitably diluted emulsions of optimized batches were observed under light microscope at 40X. From the photomicrograph, nearly spherical globules of emulsion were observed. Though this study does not give any exact estimate of size however it gives a general idea about formation of emulsion and success of the method used.




Fig.3.3 Photomicrograph of Formulation

1.5. Spreadability Studies:

Spreadability is one of the essential criteria for an emulgel. Spreadability is influenced by the formulation's viscosity. The **Model F-value** of 13.99 implies the model is significant. Only 2.73 percent of the time is there a probability that noise will cause an F-value this large. Model terms are considered significant when the P-value is less than 0.0500. In this instance, key model terms were A, A2, and B2. Model terms are not significant if the value is higher than 0.1000. Model reduction may enhance your model if it has a lot of unnecessary terms (except those needed to maintain hierarchy). Experimentally Spreadability estimation of all the runs was done was found to be in the range of 12.17 to 20.97 Gm.cm/Sec . fig 2.

Factor Coding: Actual

spreadability (gm.cm.sec)

Design Points:

● Above Surface

○ Below Surface

12.17 20.97

X1 = A

X2 = B




Fig 3.4. Plot for spreadability coefficient

1.6. Determination of Viscosity of the Formulation:

Formulated Emulgels were evaluated for viscosity using Brooke field viscometer using spindle no 4 at 30 rpm. The **Model F-value** of 10.26 implies the model is significant. There is only a 1.16% chance that an F-value this large could occur due to noise. **P-values** less than 0.0500 indicate model terms are significant. In this case A is a significant model term. Values greater than 0.1000 indicate the model terms are not significant. If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model. Experimentally viscosity estimation of all the runs was done was found to be in the range of 10348 to 23507 Cps. Fig 3.




Fig. 3.5 Plot for Viscosity

3.2 % drug release of the formulation:

The software created a quadratic model, and the model's Model F-value of 23.67 indicates that it is significant. The likelihood of noise producing an F-value this large is merely 1.29 percent. Model terms are considered significant when the P-value is less than 0.0500. B and B2 are important model terms in this instance. Model terms are not significant if the value is higher than 0.1000. Model reduction may enhance your model if it has a lot of unnecessary terms (except those needed to maintain hierarchy). Fig. 1. Experimental estimates of the drug content in all the runs were found to range from 49.53 to 83.9 percent.




Fig 3.6 plot for drug content





TABLE 3.4 POINT PREDICTION :

| Analysis | Predicted mean | Predicted median | Std. Dev. | SE mean | 95% CI low for mean | 95% CI high for mean | 95% TI low for 99% Pop | 95% TI high for 99% Pop |
|----------------|----------------|------------------|-----------|----------|---------------------|----------------------|------------------------|-------------------------|
| % drug release | 83.9 | 83.9 | 2.68676 | 2.68676 | 75.3495 | 92.4505 | 57.3688 | 110.431 |
| Viscosity | 16447.7 | 16447.7 | 2692.85 | 897.618 | 14251.3 | 18644.1 | 1417.38 | 31478 |
| spreadability | 20.97 | 20.97 | 0.914101 | 0.914101 | 18.0609 | 23.8791 | 11.9434 | 29.9966 |
| pH | 6.18333 | 6.18333 | 0.405401 | 0.135134 | 5.87171 | 6.49495 | 4.14533 | 8.22134 |


3.2 Stability study:

After being stored for three months, it was discovered that all of the created emulgel formulations were stable; there had been no change in their pharmacological composition, pH, rheological qualities, or outward appearance.

3.3 Skin irritation test (Patch Test) :

No allergic symptoms like inflammation, redness, irritation appeared on rats up to 24 hr.

% wound contraction :






Fig. Photographic representation of contraction rate showing percent wound contraction area on different post-excision days of control, Placebo control, Standard and Emulgel Formulation treated rats.

| Days | Wound Area in mm ² (% contraction) | | | | | | Epithelization period | Scar area (mm ²) |
|--------------------|---|---------------------|--------------------|--------------------|---------------------|---------------------|-----------------------|------------------------------|
| | Day 0 | Day 3 | Day 6 | Day 9 | Day 12 | Day 15 | | |
| Control(induction) | 400±4.472 | 379±5.785 | 329.3333±3.450 | 244.333333±6.552 | 117.333333±12.060 | 38±3.335 | 12.7±0.67 | 98.5±4.92 |
| Placebo | 403.333333±3.33 | 376.16667±5.750 ns | 304.1667±25.773 ns | 190.6667±7.001 *** | 92.833333±8.382 ns | 17.166667±1.276 *** | 11.46±0.21 | 91.8±7.34 |
| Standard | 400±7.303 | 349.333333±4.708 ** | 286.83333±5.322 ns | 176±6.203 *** | 28.33333±3.827 *** | 8.16667±0.7032 *** | 10.21±0.75 | 78.8±3.65 |
| Formulation | 386.66667±6.657 | 348.8333±5.603 ** | 282.5±4.008 ns | 140±3.603 *** | 23.166667±3.038 *** | 7.66667±0.8819 *** | 10.0±0.58 | 75.4±4 |

Values are the mean ± S.E.M. of six rat /treatment. Significance ^{ns}P>0.05, *P<0.05, **P<0.01, ***P<0.001, compared vs placebo, standard and formulation.








Fig. Wound Reduction in mm²

Epithelization period : The epithelization period for the Emulgel Formulation were better than the Normal control, placebo control, Standard control.

Histopathology : Based on the above observations of histopathology it can be concluded that wound healing potential of herbal formulation was faster, better and complete in group I as compared with those of standard and control group.

| | |
|---|--|
|  |  |
| Control: Note complete epidermis with secondary structures and hair follicles. H & E, 10X | Placebo: Note Incomplete epidermal closure (black arrow). Minimal angiogenesis (Yellow arrow), Minimal Horizontal collagen orientation (star), H & E, 10X |
|  |  |
| Standard: Note complete epidermis, Minimal infiltration of inflammatory cells (star). H & E, 10X | Emulgel Formulation : Note Moderate mixed collagen orientation (star), H & E, 10X |

Based on the above observations of histopathology it can be concluded that wound healing potential of herbal formulation was faster, better and complete in Emulgel formulation as compared with those of standard and control group.

CONCLUSION :

The Emulgel Formulation were developed and evaluated successfully with conclusion that Carbopol-934 with Aqueous extract of *Tridax procumbens* L., and Piperine shows excellent gelling property. Vranashodhak oil in emulsion shows good dispersion property in gel formulation. For assessment of wound healing Excision wound model were used and conclude that Optimized formulation shows better wound healing property than the control group, standard group, and placebo control group. Hence, at last it was concluded that emulgel formulation is the one of the better choices for combine use of oil and drug with promising effect in drug release as transdermal drug delivery system.

REFERENCES:

- Sri V. Formulation and Evaluation of Ketoconazole Emulgel for Topical Drug Delivery. *Int J Biol Pharm Allied Sci.* 2021;10(12 (SPECIAL ISSUE)).
- Emulsion G, Sustain FOR, Of D, For I, Diseases F. GELLIFIED EMULSION FOR SUSTAIN DELIVERY OF ITRACONAZOLE FOR TOPICAL .pdf. 2010;2(1):104–12.
- Wadher K, Patel D, Trivedi S, Umekar M. Design, Formulation and Evaluation of Topical Nimesulide Emulgel. *Int J ChemTech Res.* 2018;11(10):52–9.
- Kumar S, Prasad A, Iyer S V, Vaidya S. *Corresponding Author: Pharmacognostical, Phytochemical and Pharmacological Review on *Tridax procumbens* Linn. *Int J Pharm Biol Arch [Internet].* 2012;3(4):747–51. Available from: www.ijpba.info
- Hiwot MG. Review on wound healing activity of natural products. 2010;13–22.
- Bhagwat DA, Killedar SG, Adnaik RS. Anti-diabetic activity of leaf extract of *Tridax procumbens*. *Int J Green Pharm [Internet].* 2008 [cited 2022 Jun 3];2(2). Available from: <http://greenpharmacy.info/index.php/ijgp/article/view/46/42>
- Appiah-Opong R, Nyarko AK, Dodoo D, Gyang FN, Koram KA, Ayisi NK. Antiplasmodial activity of extracts of *Tridax procumbens* and *Phyllanthus amarus* in in vitro *Plasmodium falciparum* culture systems. *Ghana Med J.* 2011;45(4):143–50.
- Pai C. Antibacterial Activity of *Tridax procumbens* with Special Reference to Nosocomial Pathogens. *Br J Pharm Res.* 2011;1(4):164–73.
- Tiwari U, Rastogi B, Singh P, Saraf DK, Vyas SP. Immunomodulatory effects of aqueous extract of *Tridax procumbens* in experimental animals. *J Ethnopharmacol [Internet].* 2004 May [cited 2022 Jun 3];92(1):113–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/15099857/>
- Prasad LM, Gurunath KP, Chandrasekar S. Formulation and evaluation of herbal formulations (Ointment, Cream, Gel) containing *Tridax procumbens* and *Areca catachu*. *J Sci Innov Res [Internet].* 2017;6(3):97–100. Available from:

www.jsirjournal.com

11. Tiwari A, Mahadik KR, Gabhe SY. Piperine: A comprehensive review of methods of isolation, purification, and biological properties. *Med Drug Discov* [Internet]. 2020;7:100027. Available from: <https://doi.org/10.1016/j.medidd.2020.100027>
12. C. Ikewuchi J, Lkewuchi C, M. Igboh N. chemical profile of *Nypa frutican*.pdf. 2009. p. 584–550.
13. [PDF] FORMULATION, DESIGN, DEVELOPMENT AND EVALUATION OF EMULGEL FOR TOPICAL DELIVERY OF MELOXICAM IN THE TREATMENT OF RHEUMATOID ARTHRITIS | Semantic Scholar [Internet]. [cited 2022 Jun 4]. Available from: <https://www.semanticscholar.org/paper/FORMULATION%2C-DESIGN%2C-DEVELOPMENT-AND-EVALUATION-OF-D'Souza-Gude/4113365818e1a35989f46cc363bba05df8c9456e#citing-papers>
14. Pakhare A V, Deshmane S V, Deshmane SS, Biyani KR. Design and Development of Emulgel Preparation Containing Diclofenac Potassium. *Asian J Pharm*. 2017;11(4):712.
15. Mulye SP, Wadkar KA, Kondawar MS. Pelagia Research Library Der Pharmacia Sinica, 2013, 4(5):31-45 Formulation development and evaluation of Indomethacin emulgel. 2013;4(5):31–45. Available from: www.pelagiaresearchlibrary.com
16. ICH Q1A (R2) Stability testing of new drug substances and drug products | European Medicines Agency [Internet]. [cited 2022 Jun 5]. Available from: <https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products>
17. Vijay L, Kumar U. Evaluation of in vivo Wound Healing Activity of *Moringa oleifera* Bark Extracts on Different Wound Model in Rats. *Pharmacologia*. 2012;3(11):637–40.
18. Kirubanandan S, Ravi B, Renganathan S. Histological and biochemical evaluation of wound regeneration potential of *Terminalia chebula* fruits. *Asian J Pharm Clin Res*. 2016;9(1):213–8.
19. Agarwal PK, Singh A, Gaurav K, Goel S, Khanna HD, Goel RK. Evaluation of wound healing activity of extracts of plantain banana (*Musa sapientum* var. *paradisica*) in rats. *Indian J Exp Biol*. 2009;47(1):32–40.
20. Garg V, Paliwal S. Wound-healing activity of ethanolic and aqueous extracts of *Ficus benghalensis*. *J Adv Pharm Technol Res*. 2011;2(2):110.